Jounce Therapeutics has been granted a patent for antibodies targeting PD-1 to treat cancer. The patent includes a claim for an isolated nucleic acid encoding a monoclonal antibody with specific amino acid sequences. GlobalData’s report on Jounce Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Jounce Therapeutics Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Jounce Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents.

Monoclonal antibody for treating cancer by binding pd-1

Source: United States Patent and Trademark Office (USPTO). Credit: Jounce Therapeutics Inc

A recently granted patent (Publication Number: US11905329B2) discloses an isolated nucleic acid encoding a monoclonal antibody that specifically binds to human Programmed Death 1 (PD-1). The antibody is characterized by specific amino acid sequences in its heavy chain complementarity-determining regions (HCDRs) and light chain complementarity-determining regions (LCDRs). The patent claims cover various aspects of the antibody, including its composition, structure, and potential applications.

Furthermore, the patent encompasses isolated nucleic acids encoding either the heavy chain or light chain of the anti-PD-1 antibody, with specific requirements for sequence identity to known amino acid sequences. The patent also includes claims related to vectors containing the nucleic acids, isolated host cells expressing the antibody, and methods for producing the anti-PD-1 antibody through cell culture and isolation processes. The disclosed invention opens up possibilities for developing therapeutic antibodies targeting PD-1, a key immune checkpoint molecule, with potential implications for cancer immunotherapy and other medical applications.

To know more about GlobalData’s detailed insights on Jounce Therapeutics, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies